Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 33
- Registration Number
- NCT05530421
- Locations
- 🇺🇸
University of Miami, Lennar Foundation Medical Center, Coral Gables, Florida, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸University of Miami, Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
- Conditions
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05529069
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2022-08-30
- Lead Sponsor
- Hui Zeng
- Target Recruit Count
- 70
- Registration Number
- NCT05522192
- Locations
- 🇨🇳
First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05520567
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸University of Maryland, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- University Hospital, Antwerp
- Target Recruit Count
- 10
- Registration Number
- NCT05506332
- Locations
- 🇧🇪
University Hospital Antwerp, Edegem, Antwerp, Belgium
🇧🇪AZ Delta, Roeselare, West Vlaanderen, Belgium
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- BioSight Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05503355
- Locations
- 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Alfred Chung, MD
- Target Recruit Count
- 46
- Registration Number
- NCT05486481
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05471700
- Locations
- 🇨🇳
Nanfang Hospital of Southern Medical University, Guanzhou, Guandong, China
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT05464836
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Jacqueline Garcia, MD
- Target Recruit Count
- 16
- Registration Number
- NCT05455294
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.